SBIR-STTR Award

RNA based vaccines and therapeutics have emerged as great promise for HIV prevention and treatment respectively. However many obstacles still need to be overcome in particular RNA instability manufacturing problems and clinically relevant delivery mechanisms of RNA into target cells. RNA vaccine approaches have some advantages in relation to other vaccine technologies they can be delivered directly into the cytoplasm and do not require nuclear localization to generate expression Improvements of methods for mRNA synthesis and stabilization and development of improved self amplifying RNAs have recently yielded promising results. RNA approaches also stimulate the host s innate defense system in part through activation of the TLR pathways that recognize single and double stranded RNAs. Furthermore RNA based therapeutics have shown the potential to silence HIV effectively upon direct transfection in vitro but delivery into cells in vivo is still unsatisfactory. Vector based lentivirus adeno associated virus delivery to quiescent cells has proven inefficient and the vectors themselves pose a risk to the host. The primary goal of this contract solicitation is to develop improved platform technologies for the delivery of RNA into specific cells and tissues to improve the efficacy of HIV vaccines or therapeutics. Examples of HIV RNA vaccines include but are not limited to mRNA and self amplifying RNAs. Examples of RNA therapeutics include small interfering RNA siRNA microRNA miRNA microRNA antagonists aptamers messenger RNA. mRNA splice switching oligonucleotides antisense oligonucleotides and plasmid or other circular DNAs encoding messenger RNAs and transcription regulatory sequences. To enhance the efficacy of traditional HIV vaccines and therapeutics combinations of cytokines adjuvants broadly neutralizing monoclonal antibodies immune checkpoint inhibitors etc can also be co delivered in mRNA form. The short term goal of this project is to perform feasibility studies for the development and use of delivery mechanisms for RNA based HIV vaccines and therapies. The long term goal of this project is to enable a small business to bring fully developed delivery systems for RNA based HIV vaccines and therapies to the clinic and eventually to the market.